No Data
No Data
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Express News | Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Express News | Olema Reports 85% Cbr in Breast Cancer Drug Study
Express News | Olema Pharmaceuticals: Across 50 Treated Patients, Palazestrant (Op-1250) Plus Ribociclib Was Well Tolerated With No New Safety Signals
Express News | Olema Oncology Announces Promising New Data for Palazestrant in Combination With Ribociclib Presented at the 2024 Esmo Breast Cancer Congress
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares